Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD

By sjmartinez • February 13, 2025

Sciurba FC, Christenson SA, Rheault T, Bengtsson T, Rickard K, Barjaktarevic IZ. Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD. Chest. 2025 Feb;167(2):425-435. doi: 10.1016/j.chest.2024.07.168. Epub 2024 Aug 27. PMID: 39197510.

Tags: COPD, ensifentrine, exacerbation, patient-reported outcomes, Publications, Pulmonary, Critical Care & Sleep Medicine

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose[...]

Obesity mortality on the rise: A 54-year US perspective

Aamir J, Afridi MK, Sajid M, Khan TM, Qureshi S, Ahmed R, Fonarow GC, Minhas AMK, Waqas SA. Obesity mortality on the rise: A 54-year[...]

Screening for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Prospective Validation of Binary Criteria

Dixon W, Chandna S, Sack JS, Gray M, Brown CN, Poreddy S, Ha K, Schoech MR, Zucker SD. Screening for Hepatocellular Carcinoma Recurrence After Liver[...]